US FDA staff focus on safety of Arena obesity pill WASHINGTON (Reuters) - U.S. drug reviewers asked advisers to consider if Arena Pharmaceuticals' obesity drug raised the risk of tumors and heart problems. In documents posted online on Tuesday, Food and Drug Administration staff posed questions about the drug, called lorcaserin, to an advisory panel of outside experts, which will review the pill on Thursday. The FDA will make its final decision by June 27, taking into account the panel's recommendations. The FDA staff's own briefing documents have not yet been posted online. The FDA rejected Arena's lorcaserin, which is being developed in partnership with Japanese drugmaker Eisai Co Ltd, in October 2010, citing potential cancer risks. Reporting by Anna Yukhananov; editing by John Wallace